Gynecologic cancers most commonly originate in the endometrium, ovary, and cervix. Early detection and advances in treatment have improved outcomes for some cancer types, but certain gynecologic cancers, particularly recurrent or metastatic cancers of the cervix, endometrium, or ovary, have typically been linked with a poor prognosis and limited treatment options. Explore podcasts, publications, quality self-assessment tools, and on-demand education designed to improve outcomes for patients with gynecologic malignancies.
Understand when and how to use biomarker testing to guide treatment decisions in gynecologic malignancies. This guide outlines key biomarkers, testing strategies, and real-world considerations for oncology providers.
September is Gynecologic Cancer Awareness Month, a chance to highlight cancers that originate in the endometrium, ovary, and cervix, and to recognize efforts to improve patient outcomes for cancer types with poor prognoses and limited treatment options.
As we observe World Ovarian Cancer Day in 2025, health care professionals are encouraged to recognize how precision oncology is reshaping treatment paradigms and presenting new opportunities to personalize care and improve survival outcomes.
Every year, on May 8th, the world comes together to recognize World Ovarian Cancer Day. The event raises awareness for a disease that is the second most common gynecologic cancer in the US.
ACCCBuzz spoke with Scout, PhD, MA and Al Asante PA-C, MBA, ACP about their work on an innovative educational series that teaches providers how to deliver equitable gynecologic cancer care to transgender and gender non-conforming patients.
September is Ovarian Cancer and Gynecologic Cancer Awareness Month. In recognition, ACCC shares how its Barriers to Quality Care in Ovarian Cancer Phase II will test the model developed in the previous phase to optimize care for patients with advanced epithelial ovarian cancer.
Given the difficulty of managing patients with a high disease burden who are often undergoing toxic treatment regimens, maintaining high-quality ovarian cancer care can be a challenge.
Antibody-drug conjugates (ADCs) are novel therapeutic agents designed to target specific tumor markers with potent anticancer drugs. The Association of Cancer Care Centers (ACCC) is dedicated to providing up-to-date information on ADC treatment management. In this episode, CANCER BUZZ speaks with Nancy Mallett, a patient advocate, to discuss the patient’s perspective and experience receiving treatment for gynecologic cancers, particularly with ADCs such as mirvetuximab soravtansine-gynx.
CANCER BUZZ spoke to Melissa Frey, MD, MS, and Leigha Senter, MS, CGC to discuss germline and somatic testing for patients with ovarian cancer.
Presented at the 2021 ASCO Quality Care Symposium, September 24 - 25, 2021.
A deeper dive into Provider Education, Patient Education, Infrastructure, and Staffing and Services tips related to biomarker testing in ovarian cancer.
Explore this robust resource bank of curated nationally available materials to support your patients with ovarian cancer. Contents can be filtered by specifying provider or patient specific resources.
